<DOC>
	<DOCNO>NCT01774955</DOCNO>
	<brief_summary>This multicenter , prospective , observational investigation , focus antiplatelet treatment patient moderate high risk acute coronary syndrome ( TIMI risk score ≥3 ) subject percutaneous coronary intervention ( PCI ) , conduct 7 PCI capable hospital Greece . Data concern patient ' demographic , clinical/procedural characteristic contraindications/special warning precaution P2Y12 inhibitor collect initial hospitalization . Study involve 3 follow-up visit hospital discharge ( Day 30 , 6 month 12 month ) data major adverse cardiac event ( death , myocardial infarction , stroke , urgent revascularization procedure PCI CABG ) , bleed event ( accord Bleeding Academic Research Consortium criterion ) adherence antiplatelet treatment collect . In patient ticagrelor prasugrel treatment , platelet reactivity measurement VerifyNow assay perform Day 30</brief_summary>
	<brief_title>The GReek AntiPlatElet ( GRAPE ) Registry : A Multicenter Observational Prospective Investigation Antiplatelet Treatment Patients With Acute Coronary Syndrome Subjected Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Age &gt; 18 year Acute coronary syndrome moderate high risk ( TIMI risk score ≥3 ) subject PCI Informed consent Pregnancy/Breastfeeding Inability give inform consent High probability unavailable followup visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>